IFNA2, interferon alpha 2, 3440

N. diseases: 355; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE In the 1990s, interferons alpha-2 were used in the treatment of HCV and in the next decade HCV therapy was based on pegylated interferon alpha-2 in combination with ribavirin. 30685524 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE Thus, the use of latent IFNα2b can be considered again as an option for treatment of HCV infection in combination with direct acting antivirals rather than alone with improved safety profile. 31350425 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE Sustained virological response (SVR) in hepatitis C virus (HCV) patients treated with pegylated interferon α-2a and ribavirin is associated with reduced insulin resistance (IR), measured as a reduction of homeostasis model assessment (HOMA) scores after 24 weeks of therapy, and reduced fasting serum insulin and serum glucose levels. 31602234 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE Pegylated interferon α-2a/- 2b plus ribavirin was administered for either 24 or 48 weeks depending on the HCV genotype. 29529840 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE The objective of the present analysis is to describe the change in neutrophil count resulting from peglated interferon alpha 2-a (PEG-IFN α-2a) therapy in HCV-infected patients. 29872876 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE Pegylated interferon alpha 2a (PEG-IFN alpha 2a) alone, in combination with ribavirin and with or without direct acting antivirals (DAAs) is modestly effective in the treatment of chronic HCV infection. 29271660 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE ADJ higher doses of RBV based on its early pharmacokinetics-based RBV do not improve SVR rates in HCV GT4 treated in combination with peg-IFN alpha-2-a versus STD therapy. 29135370 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE Interferon α2 is an antiviral/antiproliferative protein that is currently used to treat hepatitis C infections and several forms of cancer. 28731677 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE Evaluation of Temporal Virological Responses to Interferon-α-2b plus Ribavirin among Genotype 3a Hepatitis C Virus-Infected Patients. 29141246 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE We evaluated the safety and efficacy of the hepatitis C virus (HCV) NS3/4A A protease inhibitor faldaprevir plus pegylated interferon α-2b and ribavirin (PegIFNα-2b/RBV) in Japanese patients with HCV genotype-1 infection. 27153246 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE A Bayesian Approach for Population Pharmacokinetic Modeling of Pegylated Interferon α-2a in Hepatitis C Patients. 28397081 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance. 28820468 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus. 28506030 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 GeneticVariation disease BEFREE Our purpose was to assess the combination of pretreatment IP-10 levels with IL28B SNPs as predictors of treatment response to pegylated interferon α-2a plus ribavirin in patients infected with genotype 1 hepatitis C virus in China. 26470765 2016
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 GeneticVariation disease BEFREE A Markov model was developed to estimate costs and quality-adjusted life years (QALYs) comparing between the combination of pegylated interferon alpha 2a or alpha 2b and ribavirin with a usual palliative care for genotype 1 and 6 HCV patients. 27492396 2016
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 GeneticVariation disease BEFREE Data of two cohorts of an observational multicenter study including therapy-naïve patients infected with genotype 1 hepatitis C virus (HCV) treated with dual antiviral therapy (n=7,796) with pegylated interferon alpha 2a in combination with ribavirin, or triple antiviral therapy (n=1,122) containing telaprevir or boceprevir, were analysed. 27014750 2016
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE In this randomized double-blind exploratory study, 60 naive patients of HCV infection were assigned to receive either interferonα2a (IFNα2a) (3 mIU, subcutaneous, thrice weekly), ribavirin (RBV) (1000 mg, orally, twice daily in divided doses) and placebo (n = 30) or IFNα2a, RBV and Q-e-I (5 g, orally, thrice daily in divided doses) (n = 30). 25821315 2015
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE Application of response-guided therapy (RGT) rules to the treatment of HCV infection with pegylated interferon-α2a and ribavirin, and direct-acting antivirals (DAAs) such as the NS3/4A protease inhibitors (PIs) boceprevir and telaprevir, relies on the determination of viral genotype and on-treatment HCV RNA level. 24941124 2015
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE To describe our experience using a low-accelerating-dose regimen (LADR) with pegylated interferon alpha-2a and ribavirin in treatment of hepatitis C virus (HCV) recurrence. 26034358 2015
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies. 26195509 2015
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE The study was prematurely terminated as phase III trials in hepatitis C infection indicated noninferior efficacy but inferior safety compared with pegylated-interferon-α2a. 24995515 2015
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore. 25105844 2015
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 GeneticVariation disease BEFREE Prediction of a null response to pegylated interferon α-2b plus ribavirin in patients with high viral load genotype 1b hepatitis C. 25071908 2014
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study. 25196061 2014
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.400 Biomarker disease BEFREE Hansenula-derived 20 kDa pegylated interferon alpha-2a is an effective and safe treatment for genotype 4 chronic HCV. 24730368 2014